leisure time -WSS

leisure time

author：entertainment 2025-09-30 14:10:05 - browse：2

Adam's take main illustration — Molly Ferguson/STAT

Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of people with Alzheimer’s. On Friday, we learned how: The company recruited a large number of people into its clinical trial who don’t have Alzheimer’s.

People who almost certainly had Alzheimer’s were also included in the study, but in this group, a placebo outperformed Cassava’s drug.

The conclusion, of course, is obvious: Simufilam is inactive. It’s an inert compound no more effective than a placebo. Cassava’s assertion that simufilam is showing “disease-modifying activity” falls apart given its study was opened to people who should have been ineligible because they were misdiagnosed with Alzheimer’s. Whether that was done intentionally or unwittingly isn’t known, but it’s certainly troubling and makes the case for immediate, regulatory intervention even stronger.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Many breast cancer patients receive more radiation than needed

hotspot

WSS

Kansas bar where gunfire wounded 9 last month closes permanently

Reanimated hearts work just as well for transplants, study finds

Can medical device makers keep up in the race to treat obesity?

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

How CRISPR works, explained in two minutes

Paxlovid rebound happens. Why and to whom are still a mystery

knowledge

leisure time

focus

How to save PrEP access — and even expand it

Election results set back Medicaid expansion plans

Heart attack and stroke risk calculators need revising

A fugitive mob suspect in Greece is betrayed by his passion for hometown Naples soccer champions

Supreme Court strikes down use of affirmative action

Restaurant meals are packed with calories, and we still keep eating them

Malaria cases in Florida and Texas: Here’s what you need to know

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Novavax promises a turnaround & Lilly roils the obesity market

Sage considers ways to reduce costs following FDA rejection

hotspot

Election results set back Medicaid expansion plans

Patients, doctors are clashing about side effects of hormonal birth control

The thinking behind the controversial eating disorder chatbot Tessa

With heat waves through August, officials warn of health risks

Inside the rise of 'mukbang' eating videos

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

leisure time

hotspot

focus

knowledge